Roche (Basel, Switzerland) wove a deal worth up to $425 million for Geneweave Biosciences (Los Gatos, Calif.), a private U.S. diagnostics firm with a technology aimed at fighting drug-resistant bacteria, which is considered one of health care's biggest threats. Roche (SIX: RO, ROG; OTCQX: RHHBY) said it will pay Geneweave shareholders $190 million up front, and up to $235 million in contingent product-related milestones.